• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

71.45 -1.36 (-1.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 538,347
Open 72.55
Bid (Size) 57.07 (200)
Ask (Size) 74.00 (100)
Prev. Close 72.81
Today's Range 71.05 - 74.00
52wk Range 48.20 - 85.25
Shares Outstanding 42,600,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tarsus (TARS) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
XDEMVY sales hit $173.9M with 69% growth as Tarsus expands into retinal diseases. 
Via The Motley Fool
Topics Earnings
News headline image
Tarsus Pharmaceuticals Q2 Earnings Call Highlights ↗
August 07, 2026
Tarsus Pharmaceuticals (NASDAQ:TARS) reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage... 
Via MarketBeat
Topics Earnings

Performance

YTD
-11.5%
-11.5%
1 Month
+18.8%
+18.8%
3 Month
+16.8%
+16.8%
6 Month
-4.7%
-4.7%
1 Year
+26.2%
+26.2%

More News

Read More
News headline image
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
August 06, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
August 06, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips ↗
May 06, 2026
Via Chartmill
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen ↗
March 02, 2026
Via Chartmill
News headline image
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
August 06, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
August 05, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
July 13, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline ↗
July 11, 2026
Via MarketBeat
News headline image
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
July 08, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme ↗
July 01, 2026
Via Benzinga
Topics Law Enforcement
News headline image
Tarsus to Participate in Upcoming Investor Conferences
May 28, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
May 24, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
May 24, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
May 14, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
May 07, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus (TARS) Q1 2026 Earnings Transcript ↗
May 06, 2026
Via The Motley Fool
News headline image
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
May 06, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
April 29, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
March 31, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade ↗
March 24, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
March 23, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
March 22, 2026
Via The Motley Fool
News headline image
Tarsus to Participate in Upcoming Investor Conferences
February 26, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Tarsus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Tarsus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Tarsus Pharmaceuticals, Inc. - Common Stock trade on?
Tarsus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock is TARS on the Nasdaq Stock Market
What is the current price of Tarsus Pharmaceuticals, Inc. - Common Stock?
The current price of Tarsus Pharmaceuticals, Inc. - Common Stock is 71.45
When was Tarsus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Tarsus Pharmaceuticals, Inc. - Common Stock was at 08/25/26 04:00 PM ET
What is the market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock is 3.04B
How many shares of Tarsus Pharmaceuticals, Inc. - Common Stock are outstanding?
Tarsus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap